REPEAT - Real-Life Perception of Efficacy, Attitude, Satisfaction and Safety of Levitra Therapy

Bayer

Status: Completed

Conditions: Erectile Dysfunction

Treatments: Drug: Levitra (Vardenafil, BAY38-9456)

Study type: Observational

Funder types: Industry

Identifiers

NCT00874679

13093 - LV0602MY (Other Identifier)

13048 - LV0602ZA (Other Identifier)

13112 - LV0602ID (Other Identifier)

12976 - LV0602CN (Other Identifier)

12977 - LV0602SG (Other Identifier)

13208 - LV0602TH (Other Identifier)

12975 - LV0602HR (Other Identifier)

LV0602 (Other Identifier)

14525 - LV0602FR (Other Identifier)

13416 - LV0602ES (Other Identifier)

13417 - LV0602SA (Other Identifier)

12942 - LV0602KR (Other Identifier)

12805

13067 - LV0602HU (Other Identifier)

REPEAT (Other Identifier)

13047 - LV0602SE (Other Identifier)

13600 - LV0602PL (Other Identifier)

Details and patient eligibility

About

The aim of this prospective, non-interventional post-marketing surveillance study is to obtain data on safety and efficacy of Levitra in routine treatment of erectile dysfunction. Furthermore, the data collection particularly focuses on the experience of the patient and his satisfaction with the treatment. Treatment naive patients as well as pre-treated patients will be included in the study.The maximum observation period per patient is 12 months.Besides the physician's documentation, the patient should fill out a questionnaire at every visit. The questionnaires will be handed out and collected by the physician. Furthermore, an additional questionnaire for the patient's partner can be distributed at each visit in case the partner is willing to participate.

Enrollment: 7,293 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Outpatients with diagnosis of erectile dysfunction, decision taken by the investigator to prescribe Vardenafil.

Exclusion criteria

• Exclusion criteria must be read in conjunction with the local product information. All contraindications listed in the local product information are applicable.

Trial design

7,293 participants in 1 patient group

Group 1

Treatment:

Drug: Levitra (Vardenafil, BAY38-9456)